1
|
Shi Y, Dinh J, Pelletier R, Raccor B, Yusuff N, Morgan AJ, Harbeson S, Uttamsingh V, Totah RA. Selective deuteration of bupropion slows epimerization and reduces metabolism. Bioorg Med Chem Lett 2022; 76:129009. [PMID: 36174836 DOI: 10.1016/j.bmcl.2022.129009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/31/2022] [Revised: 09/17/2022] [Accepted: 09/23/2022] [Indexed: 11/30/2022]
Abstract
Strategically replacing hydrogen with deuterium at sites of metabolism in small molecule drugs can significantly alter clearance and potentially enhance clinical safety. Bupropion is an antidepressant and smoking cessation medication with the potential to cause seizures. We hypothesized that incorporating deuterium at specific sites in bupropion may greatly reduce epimerization, potentially slow metabolism, and reduce the formation of toxic metabolites, namely hydroxybupropion which has been associated with bupropion's toxicity. Four deuterated analogues were synthesized incorporating deuterium at sites of metabolism and epimerization with the aim of altering the metabolic profile of bupropion. Spectroscopic binding and metabolism studies with bupropion and R-or S-d4 and R-or S-d10 analogs were performed with recombinant CYP2B6, human liver microsomes, and human hepatocytes. Results demonstrate that deuterated bupropion analogues exhibited 20-25% decrease in racemization and displayed a significant decrease in the formation of CYP2B6-mediated R,R - or S,S-hydroxybupropion with recombinant protein and human liver microsomes. In primary human hepatocytes, metabolism of deuterated analogs to R,R - and S,S-hydroxybupropion and threo- and erythro-hydrobupropion was significantly less than R/S-d0 bupropion. Selective deuterium substitution at metabolic soft spots in bupropion has the potential to provide a drug with a simplified pharmacokinetic profile, reduced toxicity and improved tolerability in patients.
Collapse
Affiliation(s)
- Yuanyuan Shi
- Department of Medicinal Chemistry, School of Pharmacy, University of Washington, Seattle, WA 98195, United States
| | - Jean Dinh
- Certara UK Limited, Simcyp Division, Level 2 Acero, 1 Concourse Way, Sheffield S1 2BJ, United Kingdom
| | - Robert Pelletier
- Department of Medicinal Chemistry, School of Pharmacy, University of Washington, Seattle, WA 98195, United States
| | - Brianne Raccor
- Pharmaceutical Sciences, College of Pharmacy & Health Sciences, Campbell University, Buies Creek, NC 27506, United States
| | - Naeem Yusuff
- Concert Pharmaceuticals, Inc., 65 Hayden Ave. Suite 3000N, Lexington, MA 02421, United States
| | - Adam J Morgan
- Concert Pharmaceuticals, Inc., 65 Hayden Ave. Suite 3000N, Lexington, MA 02421, United States
| | - Scott Harbeson
- Concert Pharmaceuticals, Inc., 65 Hayden Ave. Suite 3000N, Lexington, MA 02421, United States
| | - Vinita Uttamsingh
- Concert Pharmaceuticals, Inc., 65 Hayden Ave. Suite 3000N, Lexington, MA 02421, United States
| | - Rheem A Totah
- Department of Medicinal Chemistry, School of Pharmacy, University of Washington, Seattle, WA 98195, United States.
| |
Collapse
|
2
|
Raccor B, Bhadra A, Jaligama S. Quantitative determination of the effect of DDT and DDE treatments on CYP1 enzyme expression in MCF-7 Cells. Drug Metab Pharmacokinet 2019. [DOI: 10.1016/j.dmpk.2018.09.109] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|